Finally, the chemical–pharmacological properties, functional effects, such as receptor desensitization, as well as dosing protocols need to be further investigated in high-quality trials before evidence-based conclusions can be drawn on the efficacy and safety of nAChR agonist candidates in dementia. Here, CHRNA4 is linked to dementia.